Enable JavaScript to visit this website.

TTRFAP Landing Page

Pfizer is pleased to announce the 2018 Global ASPIRE Transthyretin (TTR) Amyloidosis Competitive Research Grant Awards for Junior Investigators. 

The Global ASPIRE TTR amyloidosis program underscores Pfizer’s commitment to supporting investigators with an interest in advancing their academic research in TTR amyloidosis.


The mission of the GLOBAL ASPIRE TTR amyloidosis program is as follows:

  • To support specific research in basic science and broad clinical research through a competitive grants program that advances medical knowledge in the understanding, diagnosis and treatment of TTR amyloidosis. In-scope research submissions along the entire clinical spectrum of TTR amyloidosis (from TTR familial amyloid polyneuropathy (TTR-FAP) to TTR cardiomyopathy) and including mixed phenotypes are highly encouraged.


Although recent developments have been made in the diagnosis and treatment of TTR amyloidosis, more research is needed. The goal of the 2018 GLOBAL ASPIRE TTR amyloidosis program is to further improve our understanding of the epidemiology, basic science and early diagnosis and treatment of TTR amyloidosis.

Request for Proposals

Pfizer invites junior investigators with a terminal degree (MD and/or PhD and/or PharmD or equivalent) who are developing their research careers in TTR Amyloidosis to apply for the 2018 GLOBAL ASPIRE Awards in TTR amyloidosis through submission of innovative research proposals designed to enhance our ability to understand the epidemiology, basic science and early diagnosis and treatment of patients with TTR amyloidosis.

There is no age requirement or time since receipt of terminal degree in our definition of a junior investigator.  The program is designed to support emerging researchers in ATTR, investigators continuing to develop their research career in ATTR, or investigators changing their research focus to this area.  Across most institutions this is probably going to be a range of candidates, including students who have completed their degree at the time of the actual award to fellows/residents/post-docs to Assistant Professor. See the second question under our website FAQs for additional details

2018 Research Topics: Epidemiology, Basic Science and Tools for Early Diagnosis and Treatment of Patients with TTR Amyloidosis.

2018 Areas of Research Interest

Research Requirements

Pfizer is interested in supporting research proposals that advance our understanding of the epidemiology, basic science and early diagnosis and treatment of TTR amyloidosis through research focused in the following areas:

  • Epidemiologic evaluations for TTR amyloidosis
    • Global or regionally-focused evaluations
  • Approaches for the early diagnosis of patients including:
    • Multidisciplinary approaches
    • New diagnostic algorithms
    • Imaging studies
    • Non-invasive diagnostic techniques
    • Autonomic markers of TTR-FAP disease progression
    • Risk factors for disease penetrance
    • Markers of disease progression and natural history studies
    • Genetic screening programs for families
    • Genetic counseling patient support tools
  • Evaluation of patients with TTR amyloidosis presenting with a mixed phenotype (e.g. polyneuropathy and cardiomyopathy) and including studies of patients with nonV30M mutations
    • Case Control and Cross-Sectional Studies
      • Includes examination of phenotype and genotype relationships
    • Evaluating Existing Databases for:
      • Clinical or treatment information
      • Phenotype or genomic factors
  • Retrospective analyses of the long-term efficacy and safety of tafamidis in the clinical setting for the management of TTR-FAP
    • Impact on disease progression and quality of life
      • Includes prospective or retrospective evaluations based on the tafamidis real world experience in clinical practice
      • Note: Pfizer will not supply formulated study drug
  • Mechanistic studies to advance the basic science of amyloid formation and deposition

Research Expectations

Within the specified areas of research interest, investigators are expected to:

  • Generate data to better understand important diagnostic and clinical management issues relevant to treating patients with TTR amyloidosis.
  • Proposals may include post-hoc exploratory analyses and well-designed retrospective or prospective analyses to generate and/or test hypotheses or studies to validate new assessments. Be able to complete the research within 12 months of start date.
  • Present and/or publish the results of the study.

Evaluations may include standardized assessments as well as surrogate markers that may define or predict clinical response and to identify novel diagnostic strategies. See website FAQ’s for additional guidance on topics that fall outside the scope of this program.

Available Awards

This program is exclusively open to junior investigators from around the world who have a terminal degree (MD and/or PhD and/or PharmD or equivalent) and are developing their research careers in TTR Amyloidosis. See FAQ’s on our website for additional details. Pfizer is funding research awards ranging from $25,000 USD to a maximum of $50,000 USD each. Budgets for the program must be submitted in USD and all grants will be paid in USD. Pfizer anticipates awarding up to 3 grants for the 2018 program. Award amounts include direct costs, institutional overhead costs capped at 28% per Pfizer policy, and indirect costs. Pfizer does not pay overhead on indirect costs. Study budgets will be evaluated by the external panel and if selected for award, will be reviewed for fair market value in accordance with local policies and procedures as part of the contracting process to ensure the requested funding is commensurate with the work proposed. Project duration should be no longer than 12 months.

Key Dates

Application deadline: May 14, 2018 (by 11:59pm EST in the United States) 
Notification of awards recipients and award acceptance: July, 2018
Award expected to start by: October/November 2018*
Completion of award: Research must be completed within 12 months of start date.

* Contracts not executed by December 30, 2018 may risk loss of funding